This company has been marked as potentially delisted and may not be actively trading. Digirad (DRAD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock DRAD vs. QTI, NRXS, CUTR, VRAYQ, VIVE, ELMD, STTK, ABVC, AKTX, and POCIShould you be buying Digirad stock or one of its competitors? The main competitors of Digirad include QT Imaging (QTI), NeurAxis (NRXS), Cutera (CUTR), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), Shattuck Labs (STTK), ABVC BioPharma (ABVC), Akari Therapeutics (AKTX), and Precision Optics (POCI). Digirad vs. Its Competitors QT Imaging NeurAxis Cutera ViewRay Viveve Medical Electromed Shattuck Labs ABVC BioPharma Akari Therapeutics Precision Optics Digirad (NASDAQ:DRAD) and QT Imaging (NASDAQ:QTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings. Which has more volatility and risk, DRAD or QTI? Digirad has a beta of 0.18, suggesting that its stock price is 82% less volatile than the S&P 500. Comparatively, QT Imaging has a beta of -0.2, suggesting that its stock price is 120% less volatile than the S&P 500. Do insiders & institutionals hold more shares of DRAD or QTI? 11.4% of Digirad shares are held by institutional investors. Comparatively, 24.2% of QT Imaging shares are held by institutional investors. 12.5% of Digirad shares are held by company insiders. Comparatively, 75.4% of QT Imaging shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Is DRAD or QTI more profitable? QT Imaging has a net margin of 0.00% compared to Digirad's net margin of -5.32%. QT Imaging's return on equity of 0.00% beat Digirad's return on equity.Company Net Margins Return on Equity Return on Assets Digirad-5.32% -3.75% -0.85% QT Imaging N/A N/A -65.94% Which has preferable earnings & valuation, DRAD or QTI? QT Imaging has lower revenue, but higher earnings than Digirad. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDigirad$114.18M0.08-$4.63M-$0.35-5.60QT Imaging$4.00M12.54-$4.03MN/AN/A Does the media favor DRAD or QTI? In the previous week, QT Imaging had 2 more articles in the media than Digirad. MarketBeat recorded 2 mentions for QT Imaging and 0 mentions for Digirad. QT Imaging's average media sentiment score of 0.38 beat Digirad's score of 0.00 indicating that QT Imaging is being referred to more favorably in the news media. Company Overall Sentiment Digirad Neutral QT Imaging Neutral SummaryQT Imaging beats Digirad on 8 of the 11 factors compared between the two stocks. Get Digirad News Delivered to You Automatically Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRAD vs. The Competition Export to ExcelMetricDigiradElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.33M$30.05M$5.47B$8.95BDividend Yield83.65%N/A5.25%4.06%P/E Ratio-0.623.0127.0020.10Price / Sales0.08167.14435.75120.29Price / Cash0.6941.3636.8257.86Price / Book0.192.147.985.56Net Income-$4.63M-$25.54M$3.16B$248.40M Digirad Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRADDigiradN/A$1.96+0.5%N/A-51.9%$9.33M$114.18M-0.62618QTIQT ImagingN/A$1.33-4.1%N/A+157.9%$36.16M$4.00M0.00N/ANews CoverageGap UpNRXSNeurAxis3.4757 of 5 stars$2.38-1.7%$7.00+194.1%-9.2%$17.17M$2.93M-1.2919CUTRCuteraN/A$0.04-63.9%$3.00+7,592.3%-97.2%$787K$155.21M-0.01460Gap DownHigh Trading VolumeVRAYQViewRayN/A$0.00+∞N/AN/A$18K$102.21M0.00300Gap UpHigh Trading VolumeVIVEViveve MedicalN/A$0.00flatN/AN/A$1K$6.83M0.0070High Trading VolumeELMDElectromed1.5011 of 5 stars$21.80-0.9%$38.00+74.3%+34.9%$182.82M$61.44M29.07160STTKShattuck Labs2.8411 of 5 stars$0.82+3.0%$7.50+819.6%-77.2%$37.93M$5.72M-0.59100ABVCABVC BioPharma0.6746 of 5 stars$2.42+9.0%N/A+521.2%$37.78M$510K-18.6230Positive NewsGap UpAKTXAkari Therapeutics1.3216 of 5 stars$1.17-0.4%N/A-61.1%$37.64MN/A0.009POCIPrecision OpticsN/A$4.92+0.4%N/A-19.9%$37.56M$19.10M-5.5380 Related Companies and Tools Related Companies QT Imaging Competitors NeurAxis Competitors Cutera Competitors ViewRay Competitors Viveve Medical Competitors Electromed Competitors Shattuck Labs Competitors ABVC BioPharma Competitors Akari Therapeutics Competitors Precision Optics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRAD) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Digirad Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Digirad With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DRAD Stock Alerts